Selected-GenAtlas references | SOURCE | GeneCards | NCBI Gene | Swiss-Prot | Orphanet | Ensembl |
HGNC | UniGene | Nucleotide | OMIM | UCSC |
Home Page |
FLASH GENE |
Symbol | RARA | contributors: mct/ - updated : 13-06-2015 |
HGNC name | retinoic acid receptor, alpha |
HGNC id | 9864 |
|
Corresponding disease |
| ||
Location | 17q21.2 Physical location : 38.465.422 - 38.513.894 | ||
Synonym name | |||
| |||
NPM-RAR long form | |||
Synonym symbol(s) | NR1B1, C13A4, RAR, RAR-alpha |
DNA |
TYPE | functioning gene |
STRUCTURE | 48.47 kb 9 Exon(s) |
10 Kb 5' upstream gene genomic sequence study |
---|
MAPPING | cloned | Y | linked | status | confirmed |
Map | see NF1 NF1 |
RNA |
TRANSCRIPTS | type | messenger |
---|
EXPRESSION |
Type | widely |
expressed in | (based on citations) | ||||||||||||||||||||
organ(s) |
|
cells |
|
cell lineage
cell lines
| fluid/secretion
| blood | |
at STAGE |
PROTEIN |
PHYSICAL PROPERTIES
STRUCTURE
| |
motifs/domains
| |
| |
| |
|
HOMOLOGY |
Homologene |
FAMILY | |
|
CATEGORY | transcription factor , receptor |
SUBCELLULAR LOCALIZATION | extracellular |
plasma membrane | |
intracellular | |
intracellular,cytoplasm | |
intracellular,nucleus,nucleoplasm | |
intracellular,nucleus,chromatin/chromosome |
basic FUNCTION | |
| |
|
CELLULAR PROCESS | cell life, differentiation |
nucleotide, transcription | |
cell organization/biogenesis |
PHYSIOLOGICAL PROCESS |
text | adipocyte differentiation |
PATHWAY |
metabolism |
signaling | signal transduction |
a component | |
|
INTERACTION |
DNA |
RNA |
small molecule |
protein | |
| |
| |
| |
| |
| |
| |
| |
|
cell & other |
REGULATION |
activated by | both all-trans (T-RA) and its 9-cis isomer (9-cis-RA) retinoic acids |
Other | regulated by TADA3 which regulates retinoic acid receptor RARA-mediated transactivation |
ASSOCIATED DISORDERS |
corresponding disease(s) | RARA |
Other morbid association(s) |
|
Susceptibility |
|
Variant & Polymorphism SNP | |
Candidate gene | for isolated cleft lip/palate | ||
Marker
Therapy target
| PML-RARA degradation or therapy-triggered degradation of oncoproteins could be a general strategy to eradicate cancer stem cells |
| |
ANIMAL & CELL MODELS |